CIK 0001618835 · Non-accelerated filer<br>Smaller reporting company
Evofem Biosciences, Inc.
Sign in to watch- Ticker
- EVFM
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208527075
- Phone
- (858) 550-1900
- Business address
- 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130
- Former names
- Neothetics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-06-16 | JANNEY DANIEL Director | Grant or award · Stock Option (Right to Buy) | +12,450 | 12,450 | ||
| 2015-06-16 | DEMSKI MARTHA J Director | Grant or award · Stock Option (Right to Buy) | +9,722 | 9,722 | ||
| 2015-06-16 | DEMSKI MARTHA J Director | Grant or award · Stock Option (Right to Buy) | +12,450 | 12,450 | ||
| 2015-06-16 | Gorbachev Maxim Director | Grant or award · Stock Option (Right to Buy) | +23,940 | 23,940 | ||
| 2015-06-16 | Gorbachev Maxim Director | Grant or award · Stock Option (Right to Buy) | +12,450 | 12,450 | ||
| 2015-06-12 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise | +10,848 | $1.22 | $13K | 10,848 |
| 2015-06-12 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise · Common Stock (Right to Buy) | −10,848 | 0 | ||
| 2015-03-19 | Mahaffey George W President and CEO | Purchase | +1,000 | $7.76 | $8K | 197,721 |
| 2015-02-10 | Locke Kenneth W Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +16,288 | 16,288 | ||
| 2015-02-10 | KROCHMAL LINCOLN Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +16,288 | 16,288 | ||
| 2015-02-10 | Knudson Susan A. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +45,607 | 45,607 | ||
| 2015-02-10 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Grant or award · Stock Option (Right to Buy) | +42,350 | 42,350 | ||
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Conversion | +46,311 | 46,311 | ||
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Option exercise | +1,570 | $8.54 | $13K | 47,881 |
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Shares withheld for taxes | −958 | $14.00 | $13K | 46,923 |
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Option exercise | +2,827 | $8.54 | $24K | 49,750 |
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Shares withheld for taxes | −1,725 | $14.00 | $24K | 48,025 |
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Conversion · Series A Preferred Stock | −12,578 | 0 | ||
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Conversion · Series B Preferred Stock | −104,247 | 0 | ||
| 2014-11-25 | DP VII ASSOCIATES LP 10% owner | Conversion · Series B-2 Preferred Stock | −36,913 | 0 |
Page 16 of 20 · 383 trades